ProPhase Labs to Present at the Planet MicroCap Showcase: VEGAS 2023 on Wednesday, April 26, 2023 & 1x1 Meetings on Thursday, April 27, 2023
18 avr. 2023 08h00 HE
|
ProPhase Labs, Inc.
GARDEN CITY, NY, April 18, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified biotech, genomics and diagnostics company, today announced that it will be...
ProPhase Labs Announces Record Financial Results for the year ended December 31, 2022
28 mars 2023 08h00 HE
|
ProPhase Labs, Inc.
Company highlights key strategic initiatives to grow underlying value in 2023 and beyond Company announces it is in strategic discussions to develop BE-Smart cancer test globally Company to hold a...
ProPhase Labs Announces New $6 Million Stock Repurchase Program
15 mars 2023 08h00 HE
|
ProPhase Labs, Inc.
Garden City, NY, March 15, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced that its Board of...
ProPhase Labs Announces Collaboration with mProbe, Inc. and Mayo Clinic for the Continuing Development of BE-Smart Esophageal Pre-Cancer Diagnostic Screening Test
01 mars 2023 08h00 HE
|
ProPhase Labs, Inc.
Company Outlines BE-Smart Test Roadmap for Commercialization in the U.S. Company in Early Stages of Exploring Development for Commercialization in Other Countries Garden City, NY, March 01,...
ProPhase Labs Announces Plans to Initiate Clinical Trial of Equivir (OTC)
22 févr. 2023 08h00 HE
|
ProPhase Labs, Inc.
Goal to launch commercially in Q4 2023 Garden City, NY, Feb. 22, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a growth oriented and diversified diagnostics, genomics...
ProPhase Labs Esophageal Cancer Early Detection Test (BE-smart) Featured in Peer-Reviewed Article in the International Journal of Molecular Science
16 févr. 2023 08h00 HE
|
ProPhase Labs, Inc.
Garden City, NY, Feb. 16, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced that its flagship...
ProPhase Labs Announces Plans for Major Expansion of its Pharmaloz Manufacturing, Inc. Subsidiary to Meet Growing Demand
15 févr. 2023 08h00 HE
|
ProPhase Labs, Inc.
Garden City, NY, Feb. 15, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a growth oriented and diversified diagnostics, genomics and biotech company, today provided a...
ProPhase Labs Acquires Rights to Novel Esophageal Cancer Test
19 déc. 2022 08h30 HE
|
ProPhase Labs, Inc.
GARDEN CITY, NY, Dec. 19, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. “ProPhase” (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced that it...
ProPhase Labs to Present at the Planet MicroCap Showcase: VIRTUAL 2022 on Wednesday, December 7, 2022
30 nov. 2022 08h00 HE
|
ProPhase Labs, Inc.
GARDEN CITY, NY, Nov. 30, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced that it will be...
ProPhase Labs Announces Record Third Quarter 2022 Financial Results
10 nov. 2022 08h00 HE
|
ProPhase Labs, Inc.
Q3 2022 Net Revenues of $24.2 Million (a Q3 record); Up 155% Year-over-Year Q3 2022 Net Income of $1.0 Million versus a loss in Q3 2021 Q3 2022 adjusted EBITDA of $6.3 million (a Q3...